cancer-immunotherapy

Documents about cancer-immunotherapy

• Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy#405162ClinicalTrials.gov
• The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.#442089ClinicalTrials.gov
• 18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy#623503ClinicalTrials.gov
• Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer#628542ClinicalTrials.gov
• Tumor microenvironments with an active type I IFN response are sensitive to inhibitors of heme degradation#254367IRIS
• The tumor microenvironment in triple negative breast cancer and a strategy to improve responses to immunotherapy using cryoablation and immunostimulants#273474Europe PMC
• Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer#226255ClinicalTrials.gov
• Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer#287523ClinicalTrials.gov
• Personalized Neoantigen Peptide Vaccines for Solid Tumors#353284ClinicalTrials.gov
• Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients#451522ClinicalTrials.gov
• Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer#356484ClinicalTrials.gov
• The Difference of microRNA and Circulating Tumor Cells in Blood Among Cancer Patients With Immunotherapy#123452ClinicalTrials.gov
• Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients#141097ClinicalTrials.gov
• Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium#451464ClinicalTrials.gov
• Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma#857880ClinicalTrials.gov
• Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients#174859ClinicalTrials.gov
• Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer#127593ClinicalTrials.gov
• 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness#125857ClinicalTrials.gov
• Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer.#161886NCBI PubMed Central
• Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC#245526ClinicalTrials.gov
• Combination Immunotherapy in Colorectal Cancer#329534ClinicalTrials.gov
• Immunotherapy in Uncommon and 20ins EGFR-mut Lung Cancers#366602ClinicalTrials.gov
• Proteome-based Immunotherapy of Brain Metastases From Breast Cancer#668817ClinicalTrials.gov
• A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer#283035ClinicalTrials.gov
• The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer#18619ClinicalTrials.gov
• Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer#67873ClinicalTrials.gov
• A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer#67877ClinicalTrials.gov
• Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer#152419ClinicalTrials.gov
• T-cell Based Immunotherapy for Head and Neck Cancer#172295ClinicalTrials.gov
• CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition#234413ClinicalTrials.gov
• CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy#261529ClinicalTrials.gov
• Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma#268030ClinicalTrials.gov
• Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)#303588ClinicalTrials.gov
• Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer#366610ClinicalTrials.gov
• Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer#377412ClinicalTrials.gov
• Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy#417538ClinicalTrials.gov
• Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer#432872ClinicalTrials.gov
• E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer#471460ClinicalTrials.gov
• The Role of Distinct Cancer-Associated Fibroblast Subtypes in Prostate Cancer Immunotherapy.#653321NCBI PubMed Central
• Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors#154646ClinicalTrials.gov
• A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC#858078ClinicalTrials.gov
• Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases#217034ClinicalTrials.gov
• Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer#249582ClinicalTrials.gov
• Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer#398303ClinicalTrials.gov
• Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).#226240ClinicalTrials.gov
• TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer#268031ClinicalTrials.gov
• Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer#143572ClinicalTrials.gov
• Gender matters. Sex-related differences in immunotherapy outcome in patients with non-small cell lung cancer#330406IRIS
• Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations#162447ClinicalTrials.gov
• Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.#287552ClinicalTrials.gov